Shanghai International College of Intellectual Property, Tongji University, Shanghai, China.
Ann Med. 2024 Dec;56(1):2422571. doi: 10.1080/07853890.2024.2422571. Epub 2024 Nov 1.
This study analyzes 134 invalidated traditional Chinese medicine (TCM) patents from 1984 to 2021 to explore common weaknesses and track quality progression. The findings highlight that TCM patents applied for between 2001 and 2005 face higher invalidation rates, with disputes often arising 4-7 years post-application. Disputes are concentrated in patents related to cardiovascular and cerebrovascular diseases, exacerbated by widespread geographical distribution and technology saturation. Combination patents are more prone to invalidation than single-component ones, and patents using preparation methods to describe products carry hidden risks. Additionally, citing more references positively impacts patent stability. Despite progress, TCM patents still encounter significant challenges in quality and consistency.
本研究分析了 1984 年至 2021 年的 134 项失效的中医药专利,以探讨常见的弱点并跟踪质量进展。研究结果表明,2001 年至 2005 年申请的中医药专利面临更高的失效率,申请后 4-7 年往往会出现争议。争议集中在与心脑血管疾病相关的专利上,且分布广泛,技术饱和,进一步加剧了争议。组合专利比单一组分专利更容易失效,用制备方法描述产品的专利存在潜在风险。此外,引用更多参考文献对专利稳定性有积极影响。尽管取得了进展,但中医药专利在质量和一致性方面仍面临重大挑战。